World Health Orgnanisation (WHO) said hydroxychloroquine (HCQ) will return to solidarity trial for potential treatment covid-19. The UN body had paused trials of the anti-malarial drug citing a Lancet study. The study had suggested the drug could cause more fatalities among Covid-19 patients. At a press conference in the WHO headquarters in Geneva, Director General Tedros Adhanom Ghebreyesus said, “The Executive Group received this recommendation and endorsed continuation of all arms of the solidarity trial, including hydroxychloroquine.” Watch the video for more.
E-Paper
